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A B S T R A C T
Purpose: Although sodium valproate (VPA) remains the most effective antiepileptic for generalised and
unclassiﬁed epilepsies, clinicians may be failing to discuss this treatment option because of guideline
misinterpretation. Current guidelines recommend caution regarding teratogenic risks but do not
advocate absolute avoidance.
Method: We assessed VPA prescribing in young people attending a transition epilepsy clinic. We present
six patients with idiopathic generalised epilepsy (IGE) in whom VPA had been initially avoided.
Results: Overall, the results were consistent with VPA’s superior antiepileptic efﬁcacy and ability to
reduce harmful seizure-related complications. Young people denied of VPA showed prolonged periods of
poor seizure control with medical, social and psychological complications. Following contraceptive
counselling and VPA introduction, all six patients showed improved seizure control including seizure-
freedom during follow-up of up to twenty-four months. There was also evidence of reduced seizure-
related morbidity and improved educational and occupational functioning. Prior to referral,
documentation revealed no discussion of VPA treatment options.
Conclusion: Failure to prescribe valproate for IGE, particularly when another ﬁrst-line treatment has
failed, may not be in a young woman’s best interests-particularly when they are most vulnerable to
sequelae from uncontrolled seizures. Indiscriminate avoidance of valproate needs to be recognised as a
misinterpretation of current epilepsy guidelines as it may harm young people. Although the use of
valproate demands careful consideration, there remains a strong case to always discuss this medication
because of its efﬁcacy and potential to reduce seizure-related harm. Patients must be allowed to make
their own informed decisions about effective epilepsy treatments.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Although sodium valproate (VPA) remains the most effective
antiepileptic for generalised and unclassiﬁed epilepsies [1,2],
current guidelines [3–5] appropriately recommend caution when
prescribing the drug for young women of childbearing age.
Lamotrigine and levetiracetam are commonly recommended
alternatives largely because they are considered to have fewer
and less severe adverse side-effects, including foetal teratogenici-
ty. These treatment guidelines are principally informed by
observational studies including data from pregnancy registers* Corresponding author. Tel.: +44 151 529 5770.
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pregnancies exposed to VPA, for example the EURAP registry [6]
showed a rate of 5.6% with <700 mg valproate and 24.2% with
>1500 mg valproate per day, 2.0% with <300 mg lamotrigine per
day and 4.5% with >300 mg per day. Valproate is also associated
with impaired cognitive development [7] in the absence of any
foetal malformations.
Although lamotrigine may be safer in pregnancy, it is less
effective in controlling most seizure types that occur in the
idiopathic generalised epilepsies (IGEs) and speciﬁcally tonic–
clonic seizures; the same is also true of topiramate. There are
inadequate comparative efﬁcacy data for levetiracetam. Prescrib-
ing a less effective treatment exposes the patient to a greater risk of
continuing seizures [8], consequent risk of injury (including rarely,
death) and psychological consequences and social disadvantage
[9,10].served.
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treatments when writing their guidance. This is particularly
challenging in this scenario as evidence about beneﬁt and harm
will come from many different sources. Guidance that is too risk-
averse in terms of preventing teratogenicity might expose women
to an increased risk of seizures, and particularly tonic–clonic
seizures. In addition, the clinical interpretation and implementa-
tion of guidance also requires careful consideration and over-
cautious interpretation might have the same effect. Finally,
implementation is also limited by a paucity of data that identify
the priorities and preferences of young women who are about to
start treatment for epilepsy. Such issues highlight the need for
examining signiﬁcant sequalae when operationalising epilepsy
guidelines.
2. Material and methods
We assessed the impact of treatment approaches for young
people attending a transition epilepsy clinic. We report on six
young people with an IGE seen in a specialist transition (teenager)
epilepsy clinic in the UK accrued over 18 months [11]. None of the
patients had achieved a seizure-free period of more than six
months; all had received a range of anti-epileptic medications,
either singly or in combination, but never VPA. Following
discussion of the different treatment options with the young
person and their family, all patients elected for a trial of VPA; six
were converted to valproate monotherapy and one patient
continued to receive valproate in combination with another
anti-epileptic drug. Details of the six patients are shown in Table 1.
3. Case series
Five of the six patients had experienced speciﬁc adverse
consequences from uncontrolled seizures. Prior to commencing
VPA, Cases 3 and 5 had a protracted period lasting several years of
uncontrolled seizures despite multiple trials of different high-dose
monotherapies. Cases 2 and 3 had tried monotherapies and
combination therapies and reported adverse effects including
renal calculi and sedation. Two patients required acute medical
intervention (Cases 1 and 4) for uncontrolled clusters of tonic–
clonic seizures and two experienced mental health complications
(Cases 3 and 5) that necessitated acute psychological support and
psychiatric intervention.
All six patients demonstrated improved seizure control after
commencing VPA, remaining seizure and complication-free
throughout the short duration of follow up (4–24 months).
Following seizure-cessation, social isolation and clinical depres-
sion reduced in Cases 3 and 5, school attendance improved in Case
3 and continuing higher education became a reality for Case 2.
Adverse side-effects were experienced by Cases 2, 4 and 5 but these
did not necessitate either a reduction in dose or withdrawal of the
drug. Although data were unavailable on whether patients were
sexually active or using contraception, all women after referral to
the transition service routinely received documented nurse-led
counselling on contraception and advice about pregnancy.
4. Discussion
All six patients experienced prolonged periods of poor seizure
control and consequently suffered physical, psychological and
social complications during treatment regimes that had excluded
VPA. Following the introduction of VPA, seizure control improved
in all six; all had achieved seizure freedom during the 4–24 month
follow-up. None of the patients subsequently experienced any
medical complications (including injuries) whilst on valproate and
a number demonstrated improved psychosocial functioning. Thiswould suggest that, had VPA been introduced earlier in their
management, they would have experienced fewer, if any, medical
and psychological consequences associated with poor seizure
control. Clearly, this hypothesis cannot be proven. However, the
superiority of VPA compared to other anti-epileptic medications in
enabling seizure-freedom has been demonstrated in randomised
trials. For example, alternatives to valproate such as lamotrigine
and topiramate for generalised epilepsies are likely to bring an
increased risk of treatment failure and seizures (hazard ratio 1.25
and 1.89 respectively for time to treatment failure) [1].
4.1. Uncontrolled seizures: signiﬁcant medical, psychological and
social complications
Medical complications associated with poor seizure control are
well-recognised and include accidental injuries, death (including
from sudden unexpected death in epilepsy [SUDEP] or suicide) and
mental health disorders. Anti-epileptic regimes that optimise
seizure control are considered likely to minimise the medical
complications and maximise quality of life [10].
Generalised tonic–clonic seizures during pregnancy can lead to
foetal loss through severe hypoxia, direct trauma and intracranial
haemorrhage. Convulsive (tonic–clonic) status may be associated
with foetal death in 50% of cases [12]. It is also possible that poorly
controlled seizures could adversely affect psychomotor develop-
ment of the child. Finally, poorly controlled seizures may also have
ﬁnancial consequences for the woman as well as the NHS and other
healthcare institutions.
Three of our cases experienced signiﬁcant psychological
complications, two serious and requiring psychiatric intervention,
predominantly because of poor seizure control. Clearly, there may
have been confounding factors, including their pre-morbid mental
health status and the adverse effects of medication, and
speciﬁcally, topiramate. Seizures may affect relationships, self-
esteem, continuing education, career opportunities and driving
which in turn may limit social functioning, stigma and quality of
life [10]. Such factors must be carefully considered in the
discussion of all available treatment options with young people
and their families.
4.2. Towards individualised care
Treatment options should always be tailored to a patient’s
circumstances and priorities. There should be an open and realistic
discussion about treatment alternatives that should include a
balanced discussion of relative risks and beneﬁts. Such discussions
may need to occur at the time of diagnosis, particularly in girls of
childbearing age. Whilst this might be considered a statement of
the obvious, this approach is not always followed in clinical
practice as demonstrated in all six of our cases where there was no
documented discussion on treatment choices. It may also be
difﬁcult to provide a balanced discussion without prejudicial bias
by the clinician. An over-liberal use of valproate might result in
increased foetal exposure to valproate with consequent malfor-
mations and cognitive delay. Conversely, overly restricted use of
valproate might result in unnecessary seizures and associated
consequences.
Decisions made by patients are heavily dependent upon the
information provided by clinicians. If the clinicians’ interpretation
of current evidence is that preventing teratogenicity is the priority,
the risk of teratogenicity might be emphasised in any discussion
and valproate might not even be offered as a treatment option.
Decisions made in clinic consultations might be helped by
better evidence about the priorities and preferences of young
people with epilepsy although there is a currently a dearth of such
evidence.
Table 1
Clinical characteristics and seizure-related outcomes before and after sodium valproate.
Patient no:
sex, age
ILAE diagnosis (investigations) Failed treatment regimens
prior to commencing
valproate
Type and frequency of
seizures
Complications before valproate
monotherapy
Outcomes after commencing valproate
Uncontrolled seizures with complications
1: F, 17 JME diagnosed aged 12.
Tonic–clonic seizures
(i) LEV 3g daily (maximum
dose)a
Continuing generalised
tonic–clonic seizures every
other month typically
around menstruation
Uncontrolled seizures. Seizure whilst using
hair straighteners resulting in deep lower
limb burns requiring extensive plastic
surgery
Remained seizure-free throughout 14-
month follow-up. Referred to nurse-led
pre-conceptual counselling clinic
2: F, 20 IGE (EEG markedly abnormal.
Frequent generalised onset.
Rhythmic spike and slow waved
activity and poly spike activity)
(i) LEV 4g daily
(ii) TOP 400mg daily
(iii) LTGa
Regular tonic clonic
seizures every 6 weeks.
Daily absence seizures
Uncontrolled seizures. Lamotrigine side
effects: admitted with renal calculus whilst
on lamotrigine (listed as common side
effect in British National Formulary)
Remained seizure-free throughout 4-
month follow-up. Absences reduced to
few times per week having previously
been daily. Tiredness the only reported
side effect
3: F, 17 IGE diagnosed aged 12
(tonic–clonic and absence seizures.
MR brain unremarkable)
(i) LTG (maximum dose)
(ii) LEV
(iii) TOP 150mg daily and
clobazam
(iv) LEV 1.5 g daily and
lamotrigine 600mg dailya
Multiple absence seizures
daily
Uncontrolled seizures. Levetiracetam side
effects: severe sedation (‘‘sleeping for 16
hours/day’’). Depression: ‘‘tearfulness,
problems at school. . .lost interest in not
just her school work but also her friends
and leisure pursuits’’ – considered related
to ongoing intrusive seizures
Remained seizure-free throughout 20-
month follow-up. Mood improved –
may have beneﬁted from both
antiepileptic and antidepressant effects
of VPA
4: F, 19 IGE (CT head unremarkable) (i) LEV 4g dailya Tonic–clonic seizures every
2 months, typically within
an hour of waking, had
never achieved seizure
freedom for more than 4
months
Uncontrolled seizures. Worse with alcohol.
Fall during seizure resulting in subluxed
upper central incisors and aceration to
upper lip mucosa requiring suturing and
splinting
Remained seizure-free throughout 4-
month follow-up. Advised to avoid
switching generic brands of valproate.
Enrolled in university education.
Occasional vomiting with generic
formula, appetite increase, hair loss.
Explanation given on contraception and
availability of different choices given
that P450 enzyme inducers would not
be used. Commenced on folic acid
5: F, 24 IGE diagnosed at 11 months (EEG
showed generalised polyspike and
wave abnormality induced by
hyperventilation and associated
with blinking)
(i) ETX
(ii) CBZ
(iii) LTG 600mg daily and
LEV 1g daily
(iv) LTG 600mg daily, LEV
1g daily and clobazam
10mg daily with PRN
clobazam
(v) CBZ and LEV 2.5 g dailya
Treated initially with VPA
as a young child but was
discontinued as she grew
older and was switched to
ETX. Subsequentworsening
control of seizures during
stressful periods revising
for GCSE school
examinations
Uncontrolled seizures. Suffered multiple
seizureswhilst attempting to go on holiday.
Required referral to clinical
neuropsychology for stress counselling and
CBT on her return. Substantial seizure
psychosocial complications identiﬁed: ‘‘She
now feels her epilepsy has affected her
social life. . .[she is] unable to do very
straight forward things such as get on a bus
on her own. . .she ﬁnds it difﬁcult at this
time in her life, where she has stressful
factors such as college exams and other
teenage worries. . .’’
Remained seizure-free throughout 24-
month follow-up on VPA 1g daily and
LTG 150mg daily. Hair loss and ﬁne
tremor noted. Orlistat commenced for
weight gain and driving licence
successfully applied for
Uncontrolled seizures without complications
6: M, 15 JME diagnosed aged 14 (Myoclonic,
tonic–clonic and absence seizures,
EEG showed generalised spike and
wave discharges at 4Hz)
(i) LEV2gdaily for 4months
(ii) LTG 400mg daily added
for 5 months before referral
for second opiniona
Daily myoclonic seizures
and weekly tonic–clonic
seizures
Uncontrolled seizures. ‘‘Withdrawn,
refused to attend school and talked about
self-harm because of daily myoclonic
seizures’’
Remained seizure-free throughout 5-
month follow-up. Increased appetite
but no signiﬁcant weight gain. School
attendance improved and participating
in all previous activities and interests
on 1.2 g VPA daily
CBZ – carbamazepine; CLB – clobazam; ETX – ethosuximide; LEV – levetiracetam; LTG – lamotrigine; VPA – valproate.
a No documented discussion or offering of valproate to patient before referral to our clinic.
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T.B. Mole et al. / Seizure 24 (2015) 127–130130In conclusion, VPA is clearly an effective anti-epileptic drug but
it may equally be associated with signiﬁcant adverse side-effects
including foetal teratogenicity and cognitive and language
dysfunction in children exposed to the drug, particularly in the
ﬁrst few months of pregnancy. Valproate will always be a
treatment option for the treatment of the generalised epilepsies
and this must be openly and honestly discussed with the young
person or teenager, and where appropriate their family. This must
include the discussion of the implications of poor seizure control
and its consequences as well as the implications of an unplanned
pregnancy on the foetus. Other factors that are relevant to VPA
prescribing to women include the risk of weight gain and
endocrinological side effects. Whilst there has not been a
sufﬁciently powered study linking VPA to polycystic ovary
syndrome (PCOS) the body of evidence as it stands, strongly
suggests that VPA has the potential to cause this disorder – which
may be relevant to young women. This does not mean that VPA
cannot be used, but it does mean that weight and (if appropriate)
the regularity of periods should be checked regularly as a bare
minimum. The teenager’s decision will be based upon their
practical priorities at the time of this discussion; clearly, their
priorities may subsequently change depending on the young
person’s situation, as this is a critical and dynamic time of their life.
In a woman who is at risk of becoming pregnant, if the decision in
her best interests is to prescribe valproate, then it should be at the
lowest effective dose and in conjunction with folic acid and advice
on contraception and pregnancy. Ultimately the woman needs to
be given reliable, information with which to make an informed
choice, and she may choose to continue taking VPA when planning
a pregnancy, particularly if her epilepsy has been resistant to other
treatments. It is important that information given provides
patients with a balanced and un-prejudiced view about different
treatment options that should include valproate. It must be
emphasised that current epilepsy guidelines encourage this
individual, tailored approach rather than attempting absolute
risk-avoidance or physician-centred decision-making. Current
guidelines do not state that valproate should be universally
avoided and patients must be allowed to make their own informed
decisions about their epilepsy treatment.Funding
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